Lydia Wunderle

2.1k total citations · 1 hit paper
17 papers, 1.5k citations indexed

About

Lydia Wunderle is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Lydia Wunderle has authored 17 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 10 papers in Genetics and 10 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Lydia Wunderle's work include Chronic Myeloid Leukemia Treatments (13 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Acute Lymphoblastic Leukemia research (10 papers). Lydia Wunderle is often cited by papers focused on Chronic Myeloid Leukemia Treatments (13 papers), Chronic Lymphocytic Leukemia Research (10 papers) and Acute Lymphoblastic Leukemia research (10 papers). Lydia Wunderle collaborates with scholars based in Germany, United States and United Kingdom. Lydia Wunderle's co-authors include Oliver G. Ottmann, Barbara Waßmann, Dieter Hoelzer, Andreas Hochhaus, Margaret Dugan, Maher Albitar, Leila Alland, Francis J. Giles, Kapil N. Bhalla and Jörge E. Cortes and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Lydia Wunderle

15 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

2006 970 citations Hagop M. Kantarjian, Francis J. Giles et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Lydia Wunderle

Since Specialization

Citations

This map shows the geographic impact of Lydia Wunderle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lydia Wunderle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lydia Wunderle more than expected).

Fields of papers citing papers by Lydia Wunderle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lydia Wunderle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lydia Wunderle. The network helps show where Lydia Wunderle may publish in the future.

Co-authorship network of co-authors of Lydia Wunderle

This figure shows the co-authorship network connecting the top 25 collaborators of Lydia Wunderle. A scholar is included among the top collaborators of Lydia Wunderle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lydia Wunderle. Lydia Wunderle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Results from the completed dose-finding part of phase 2 study of the innate cell engager acimtamig (AFM13) in combination with AlloNK (AB-101) in relapsed or refractory classical Hodgkin lymphoma (LuminICE-203). 2025 ·Journal of Clinical Oncology ·Joseph Maakaron, Tatyana Feldman, Todd A. Fehniger, Gunjan L. Shah, Amitkumar Mehta, Dipenkumar Modi, Matthew Mei, Craig S. Sauter, Rashmi Khanal, Stefan K. Barta, Joseph Maly, Michael Emig, Lydia Wunderle, (unknown), (unknown), (unknown), (unknown), Thorsten Graef, Heather K. Raymon, Alison J. Moskowitz	0
2	Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study 2024 ·Blood ·Joseph Maakaron, Dipenkumar Modi, Matthew Mei, Tatyana Feldman, Gunjan L. Shah, Amitkumar Mehta, Craig S. Sauter, Rashmi Khanal, Stefan K. Barta, Michael Emig, Lydia Wunderle, (unknown), (unknown), (unknown), Thorsten Graef, Heather K. Raymon, Alison J. Moskowitz	2
3	Engaging Innate Immunity By AFM28, an Innate Cell Engager (ICE®) Targeting CD123-Positive Leukemic Cells in Patients with Relapsed/Refractory Acute Myeloid Leukemia: Safety and Efficacy Results of a First-in-Human Phase 1 Study 2024 ·Blood ·Pau Montesinos, Montserrat Arnán, Stéphane de Botton, María Calbacho, (unknown), Pierre Bories, Belén Ansoleaga, Thomas Hueso, Naval Daver, Lydia Wunderle, A. Harstrick, (unknown), (unknown), (unknown), Tania Witte, Eugene L. Saenger, Christian Récher	3
4	A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia 2020 ·BMC Pharmacology and Toxicology ·Fabian Lang, Lydia Wunderle, (unknown), Eberhard Schleyer, Monika Brüggemann, Hubert Serve, Susanne Schnittger, Nicola Gökbuget, Roman Pfeifer, Sebastian Wagner, Kevin E. Ashelford, Gesine Bug, Oliver G. Ottmann	28
5	Dasatinib and Azacitidine Followed by Haploidentical Stem Cell Transplant for Chronic Myeloid Leukemia with Evolving Myelodysplasia: A Case Report and Review of Treatment Options 2017 ·American Journal of Case Reports ·Fabian Lang, Lydia Wunderle, Roman Pfeifer, Susanne Schnittger, Gesine Bug, Oliver G. Ottmann	3
6	In Adult Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, The Negative Prognostic Impact Of IKZF1, CDKN2A/B and PAX5 Deletions Is Not Abrogated By Allogeneic Stem Cell Transplantation In First Complete Remission 2013 ·Blood ·Roman Pfeifer, (unknown), (unknown), Stéphanie Fey, Julia Obländer, Verena Nowak, Lydia Wunderle, Fabian Lang, Dieter Hoelzer, Wolf‐Karsten Hofmann, Nicola Goekbuget, Oliver G. Ottmann, Daniel Nowak	2
7	Safety and Efficacy Of BEZ235, a Dual PI3-Kinase /mTOR Inhibitor, In Adult Patients With Relapsed Or Refractory Acute Leukemia: Results Of a Phase I Study 2013 ·Blood ·Lydia Wunderle, (unknown), Fabian Lang, Andrea Wolf, Eberhard Schleyer, Hubert Serve, Nicola Goekbuget, Roman Pfeifer, Gesine Bug, Oliver G. Ottmann	14
8	Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia 2012 ·Leukemia ·Roman Pfeifer, Thoralf Lange, (unknown), Barbara Waßmann, Jacqueline Maier, Anja Binckebanck, Aristoteles Giagounidis, (unknown), Marc Schmalzing, Ulrich Dührsen, Lydia Wunderle, Hubert Serve, Patrick T. Bruck, Anja Schmidt, D. Hoelzer, Oliver G. Ottmann	52
9	Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib 2008 ·Haematologica ·Paul La Rosée, (unknown), Helmut König, Nicolai Härtel, Thomas Ernst, J. F. Debatin, Martin Mueller, Philipp Erben, Anja Binckebanck, Lydia Wunderle, Yaping Shou, Margaret Dugan, R. Hehlmann, Oliver G. Ottmann, Andreas Hochhaus	31
10	Imatinib compared with chemotherapy as front‐line treatment of elderly patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ALL) 2007 ·Cancer ·Oliver G. Ottmann, Barbara Waßmann, Roman Pfeifer, Aristoteles Giagounidis, Matthias Stelljes, Ulrich Dührsen, Marc Schmalzing, Lydia Wunderle, Anja Binckebanck, Dieter Hoelzer	151
11	Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) 2007 ·Blood ·Roman Pfeifer, Barbara Waßmann, Anna Pavlova, Lydia Wunderle, Johannes Oldenburg, Anja Binckebanck, Thoralf Lange, Andreas Hochhaus, (unknown), Patrick T. Bruck, Dieter Hoelzer, Oliver G. Ottmann	173
12	Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL breakdown → 2006 ·New England Journal of Medicine ·Hagop M. Kantarjian, Francis J. Giles, Lydia Wunderle, Kapil N. Bhalla, Susan O’Brien, Barbara Waßmann, Chiaki Tanaka, Paul W. Manley, P. Rae, William Mietlowski, (unknown), Andreas Hochhaus, James D. Griffin, Dieter Hoelzer, Maher Albitar, Margaret Dugan, Jörge E. Cortes, Leila Alland, Oliver G. Ottmann	970
13	Bcr-Abl Tyrosine Kinase Domain Mutations Both Pre-Exist and Develop during Imatinib Treatment and Are Responsible for Resistance in Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL). 2006 ·Blood ·Roman Pfeifer, Barbara Waßmann, Anna Pavlova, Lydia Wunderle, (unknown), Andreas Hochhaus, Dieter Hoelzer, Oliver G. Ottmann	2
14	Sustained Molecular Responses to Dasatanib (SPRYCEL®) in Patients with Philadelphia Chromosome-Positive (Ph(+)) Acute Lymphoblastic Leukemia (ALL) or Lymphoid Blast Phase (LyBP) Chronic Myeloid Leukemia after Imatinib (IM) Failure: A Single-Center Experience. 2006 ·Blood ·(unknown), Roman Pfeifer, Lydia Wunderle, (unknown), Barbara Waßmann, (unknown), Ashwin Gollerkeri, Dieter Hoelzer, Oliver G. Ottmann	1
15	Monitoring of Phosphorylated CRKL in Imatinib Resistant Patients with BCR-ABL Positive Leukemias Expressing BCR-ABL Mutants Treated with AMN107. 2005 ·Blood ·Paul La Rosée, (unknown), Thomas Ernst, Helmut König, Philipp Erben, Martin Müller, Thomas Schenk, Michael Emig, Anja Binckebanck, Lydia Wunderle, Leila Alland, Peter Schuld, Rüdiger Hehlmann, Oliver G. Ottmann, Andreas Hochhaus	0
16	AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has Significant Activity in Imatinib-Resistant Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome Positive Acute Lymphoid Leukemia (Ph + ALL). 2005 ·Blood ·Hagop M. Kantarjian, (unknown), Jörge E. Cortes, (unknown), Lydia Wunderle, Kapil N. Bhalla, Dan Jones, Andreas Hochhaus, P. Rae, Leila Alland, Michael J. Dugan, Maher Albitar, Francis J. Giles	17
17	Pattern and Evolution of BCR-ABL Kinase Domain Mutations in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Developing Resistance to Imatinib. 2005 ·Blood ·Roman Pfeifer, Barbara Waßmann, (unknown), Martin Mueller, Lydia Wunderle, (unknown), Johannes Oldenburg, Andreas Hochhaus, Harald Gschaidmeier, Dieter Hoelzer, Oliver G. Ottmann	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact